Health Condition 1: null- Suffering from Type-2 Diabetes Mellitus
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes 2. Patients with HbA1c >7.5% 3. Patients with/without diabetic neuropathy 5. Patients willing to give written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patient with type 1 diabetes 2. Patientwith stents/pacemaker/CABG/advance cardiomyopathy 3. Patients with hepatic diseases 4. Patients with chronic kidney diseases 5. Patient taking immunosuppressive medications, glucocorticoids 6. Patient with chronic alcoholism/drug abuse 7. Pregnant & lactating women 8. Patients not willing to come for follow up as per protocol. 9. Patients who have participated in any other clinical study over the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduces the glycemic index as well as pro-inflammatory cytokines like IL6, TNF-alpha, hsCRP. It also reduced the elevated level of homocysteine and increased the level of vitamin D3. The patients reported feeling of well being, improve in appetite and sleep pattern.Timepoint: Gradual Improvement (1 month to 3 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in Glycemic Index and reduction in diabetic complications.Timepoint: Gradual Improvement (1 month to 3 months) | — |
Countries
India
Contacts
Institute of Medical Sciences, Banaras Hindu University